Ascendiant Capital Maintains Buy on Atossa Therapeutics, Raises Price Target to $25
Benzinga Newsdesk 1 month ago
Analyst RatingsNewsPrice Target
Ascendiant Capital analyst Edward Woo maintains Atossa Therapeutics (NASDAQ:ATOS) with a Buy and raises the price target from $24 to $25.
Ascendiant Capital analyst Edward Woo maintains Atossa Therapeutics (NASDAQ:ATOS) with a Buy and raises the price target from $24 to $25.